<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22931" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV in Pregnancy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Irshad</surname>
            <given-names>Usama</given-names>
          </name>
          <aff>King Edward Medical University / Mayo Hospital Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahdy</surname>
            <given-names>Heba</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tonismae</surname>
            <given-names>Tiffany</given-names>
          </name>
          <aff>Johns Hopkins All Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Usama Irshad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heba Mahdy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tiffany Tonismae declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22931.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Several thousand HIV positive pregnant women give birth in the US annually. With proper management, these women can achieve viral suppression to undetectable levels and have a normal conception, pregnancy, and vaginal delivery. This activity outlines the evaluation and management of HIV in pregnant women and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of the perinatal spread of HIV in pregnant women.</p></list-item><list-item><p>Summarize the evaluation of women with HIV.</p></list-item><list-item><p>Outline the management options available for HIV in pregnant women.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22931&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22931">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22931.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The study of HIV during pregnancy holds great significance because many women are first diagnosed with HIV during pregnancy. Similarly, it is equally important in cases where one or both partners are HIV positive and wish to conceive. During the recent years, universal HIV prenatal testing, antiretroviral therapy (ART), scheduled cesarean delivery for HIV positive women with elevated viral loads, appropriate ART for infants and avoidance of breastfeeding have shown encouraging results, and the Centers for Disease Control and Prevention now aims to eliminate HIV transmission from mother to child by reducing its incidence to &#x0003c;1 infection per 100,000 live births.</p>
      </sec>
      <sec id="article-22931.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HIV disease in humans can be caused by infection with either HIV-1 or HIV-2. HIV-1 is more prevalent of the two, has higher infectivity, virulence, and greater spread through heterosexual sex. The transmission rate of HIV from mother to child (vertical transmission) is 20% to 25% for HIV-1 versus about 5% for HIV-2.<xref ref-type="bibr" rid="article-22931.r1">[1]</xref>&#x000a0;Vertical transmission of HIV is possible not only throughout pregnancy but also during childbirth and breastfeeding. Together this is termed as the perinatal transmission of HIV.</p>
      </sec>
      <sec id="article-22931.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>According to one estimate, around 5,000 HIV positive women give birth in the United States every year.<xref ref-type="bibr" rid="article-22931.r2">[2]</xref>&#x000a0;Following current recommendations regarding HIV and pregnancy, both the United States and Europe have witnessed a steep decline in perinatal HIV transmission to 1% or less.<xref ref-type="bibr" rid="article-22931.r3">[3]</xref> In the United States, black infants have 5 times increased incidence of perinatal HIV compared to white infants.<xref ref-type="bibr" rid="article-22931.r2">[2]</xref> According to a report by the Centers for Disease Control and Prevention, only 44 HIV positive infants were born in the United States in the year 2016, with the incidence of perinatal HIV transmission being as low as 1.1 out of 100,000 live births.<xref ref-type="bibr" rid="article-22931.r4">[4]</xref>&#x000a0;Globally, with the increasing availability of ART to pregnant women, the number of new HIV cases among children has decreased by 47% since 2010 according to the Joint United Nations Programme on HIV/AIDS (UNAIDS).</p>
      </sec>
      <sec id="article-22931.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History and physical in HIV-positive pregnant women should focus on identifying health issues in the mother who may directly or indirectly affect the health of the fetus. Special consideration should be given to any history of opportunistic infections, sexually transmitted infections, substance abuse, and vaccination status. New symptoms like fever should immediately alert the physician to the possibility of an undiagnosed opportunistic infection.</p>
        <p>Physical examination should aim to pick up signs like thrush, which may be an indicator of an advanced HIV infection. Special attention should also be paid to signs of other STIs which may be present along with HIV. A thorough examination should be performed to look for any stigmata of liver disease.</p>
      </sec>
      <sec id="article-22931.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Following investigations are required to assess the infection and follow up with treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Gestational age estimation</bold>
</p>
          </list-item>
        </list>
        <p>Ultrasound estimation in the first trimester&#x000a0;is preferred over the LMP method for calculating the expected date of delivery (EDD).<xref ref-type="bibr" rid="article-22931.r5">[5]</xref> Especially important in HIV positive pregnant women because some of them may require early delivery in order to diminish the risk of perinatal transmission of the virus.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>CD4 cell counts</bold>
</p>
          </list-item>
        </list>
        <p>Done on the first visit and then every trimester during pregnancy.&#x000a0;</p>
        <p>One physiological effect of pregnancy is a fall in the absolute CD4 count, but the percentage CD4 count remains unchanged and may be monitored instead. However, absolute CD4 counts are still used to check, e.g., ART response.<xref ref-type="bibr" rid="article-22931.r6">[6]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Viral load measurement</bold>
</p>
          </list-item>
        </list>
        <p>According to the Panel of Antiretroviral Guidelines for Adults and Adolescents, viral load should be assessed at the time of the initial visit, again at the time of starting ART, two weeks after starting ART and then monthly until the patient achieves complete suppression of the virus after which it can be reduced to testing once every three months for the remaining pregnancy duration. At 34-36 weeks, another estimation of the viral RNA load is made to decide the mode of delivery and gestational age for delivery.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Drug resistance testing</bold>
</p>
          </list-item>
        </list>
        <p>In the United States, the Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission recommends doing drug resistance testing before ART initiation and modification in all cases where the HIV RNA levels are &#x0003e;500 to 1000 copies/mL which is the threshold for drug resistance testing.</p>
        <p>In cases where a pregnant HIV positive woman has never received ART, especially if she is presenting late in her pregnancy, ART should be started before the drug resistance testing results are available and can be later modified accordingly.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>ART toxicity monitoring</bold>
</p>
          </list-item>
        </list>
        <p>The Panel of Antiretroviral Guidelines for Adults and Adolescents in the United States suggests doing CBC, BUN, creatinine, and liver function tests before starting ART. These should then be repeated every three to six months. Additionally, urinalysis is recommended before starting a tenofovir-containing ART regimen and then every six months.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>HLA-B*5701 testing</bold>
</p>
          </list-item>
        </list>
        <p>This should be done if abacavir-containing ART regimen is to be initiated</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Gestational diabetes screening</bold>
</p>
          </list-item>
        </list>
        <p>For HIV positive pregnant women on ART regimens containing protease inhibitors, GDM screening should be performed earlier than the usual recommended age of 24-28 weeks because protease inhibitors tend to increase glucose intolerance in HIV-infected individuals.<xref ref-type="bibr" rid="article-22931.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Viral hepatitis testing</bold>
</p>
          </list-item>
        </list>
        <p>Because of frequent coinfection, HIV positive pregnant women are screened for both HBV and HCV. In addition to the usual anti-HCV IgG and IgM, a patient with CD4 counts below 100/microL, and having a history of HCV risk factors should be given PCR testing for HCV RNA because serological testing for HCV can be falsely negative.</p>
        <p>If the patient is HBV-negative, give them the recombinant HBV vaccination (considered safe in pregnancy). If HBV infection is confirmed, antivirals having activity against both HIV and HBV can be given.</p>
        <p>Educate HCV negative patients about the risk factors for HCV. Acute HCV infection during pregnancy in HIV infected women increases the risk of vertical transmission of HCV to the fetus.<xref ref-type="bibr" rid="article-22931.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Tuberculosis testing</bold>
</p>
          </list-item>
        </list>
        <p>Testing for tuberculosis is recommended for all patients with diagnosed HIV infection.<xref ref-type="bibr" rid="article-22931.r9">[9]</xref> It can be safely done in HIV infected pregnant women if it has not been previously performed or if HIV is diagnosed for the first time during pregnancy. This is especially important because latent tuberculosis is more likely to transition into active infection in individuals who are HIV positive.<xref ref-type="bibr" rid="article-22931.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>STI screening</bold>
</p>
          </list-item>
        </list>
        <p>Because of the risk of stillbirth, low birth weight, premature preterm rupture of membranes, and preterm delivery, HIV positive pregnant women are screened for syphilis, gonorrhea, chlamydia, and trichomonas infection. Syphilis infection of HIV infected pregnant women has been found to increase vertical transmission risk of HIV.<xref ref-type="bibr" rid="article-22931.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Toxoplasma and CMV testing</bold>
</p>
          </list-item>
        </list>
        <p>Unlike in HIV-negative women, serological testing for <italic toggle="yes">Toxoplasma gondii </italic>is recommended in HIV infected pregnant women. If <italic toggle="yes">T. gondii </italic>IgG is positive and CD4 count below 100/mL, then suppressive therapy is started.</p>
        <p>Most HIV positive pregnant women have already been exposed to CMV, so no CMV serological testing is recommended.<xref ref-type="bibr" rid="article-22931.r12">[12]</xref> At present, there are no recommended drugs to prevent congenital CMV infection. Only active CMV infection in HIV infected pregnant women is treated.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Vaccination assessment</bold>
</p>
          </list-item>
        </list>
        <p>In addition to the Tdap and influenza immunizations routinely given during pregnancy, HIV positive pregnant women should also receive pneumococcal and Hepatitis A &#x00026; B (according to past infection status) vaccinations.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>General Counselling</bold>
</p>
          </list-item>
        </list>
        <p>This should include counseling about modifiable behaviors, which can lead to increased chances of perinatal HIV transmission, e.g., tobacco, alcohol, illicit drug use, unprotected sex in a non-monogamous relationship. Regular condom use should be encouraged.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Psychiatric evaluation</bold>
</p>
          </list-item>
        </list>
        <p>Evaluate the patient for any history of difficulty adhering to medication regimens, depression, anxiety, and domestic/intimate partner violence. These should prompt the need for supportive care.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Evaluation for opportunistic infections</bold>
</p>
          </list-item>
        </list>
        <p>TMP-SMX is given to pregnant patients with CD4 cell count below 100/mL (<italic toggle="yes">Toxoplasma gondii</italic> and PCP) and 200/miroL (PCP) for prophylaxis against these opportunistic infections. This is done after discussing the possible teratogenicity risk of TMP-SMX with the patient.<xref ref-type="bibr" rid="article-22931.r13">[13]</xref><xref ref-type="bibr" rid="article-22931.r14">[14]</xref></p>
        <p>Azithromycin is used as a prophylaxis against disseminated <italic toggle="yes">Mycobacterium avium</italic> complex infection in pregnant patients with CD4 cell count &#x0003c;50/mL.</p>
      </sec>
      <sec id="article-22931.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment protocols vary from the time of conception until birth.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Preconception Management and Counseling</bold>
</p>
          </list-item>
        </list>
        <p>Counseling should be tailored according to the needs and HIV status of partners wishing to conceive. According to the CDC guidelines, in serodiscordant couples, where the partner with HIV is on ART and has an undetectable viral load, unprotected sexual intercourse is associated with no risk of sexual transmission of HIV.<xref ref-type="bibr" rid="article-22931.r15">[15]</xref><xref ref-type="bibr" rid="article-22931.r16">[16]</xref>&#x000a0;Two plasma viral load readings below detectable levels, recorded at least three months apart, are required to show successful (sustained) viral suppression.</p>
        <p>In serodiscordant couples wishing to conceive where viral suppression status is unknown, or it has not been successfully attained, the partner without HIV can be given pre-exposure prophylaxis, and unprotected sexual intercourse can be limited to peak fertility period in each cycle. This is done to limit the sexual transmission of HIV.<xref ref-type="bibr" rid="article-22931.r17">[17]</xref><xref ref-type="bibr" rid="article-22931.r18">[18]</xref></p>
        <p>Starting ART before conception not only prevents sexual transmission between partners, it also reduces perinatal transmission of HIV.<xref ref-type="bibr" rid="article-22931.r19">[19]</xref></p>
        <p>To further eliminate the chances of sexual transmission of HIV, HIV positive women with HIV negative partners and wishing to conceive, may receive assisted insemination. If an HIV positive man and an HIV negative woman wish to conceive, sperm preparation techniques combined with intrauterine insemination or in vitro fertilization may be considered. A sperm donor may also be used in such cases.</p>
        <p>Genital tract inflammation, as seen in genital tract infections, increases HIV viral shedding.<xref ref-type="bibr" rid="article-22931.r20">[20]</xref>&#x000a0;It is therefore recommended to screen both partners for genital tract infections before trying to conceive.</p>
        <p>Both HIV and ART are associated with increased infertility. So infertility works up in such couples should be started early, ideally, after failure to conceive after six months of unprotected sex.<xref ref-type="bibr" rid="article-22931.r21">[21]</xref><xref ref-type="bibr" rid="article-22931.r22">[22]</xref></p>
        <p>In couples where both partners are HIV positive, it is recommended to start ART and attain sustained viral suppression before trying to conceive.</p>
        <p>Pregnant HIV negative women with HIV positive partners should be screened for HIV on initial visits unless they decide to opt-out of it. They should receive counseling about regular condom use and ART adherence in their partner. Such women (living with HIV positive partners) should ideally be tested for HIV every trimester.</p>
        <p>Counseling for HIV negative men trying to conceive with HIV positive partners should include the importance of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) adherence in their partner. Such men should be tested for HIV at least every three months during the period when they are having unprotected sex with their partners in order to try to conceive.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Antepartum Management</bold>
</p>
          </list-item>
        </list>
        <p>In addition to the routine assessment for all pregnant women, HIV positive pregnant women should be assessed as described above under &#x02018;evaluation.&#x02019;</p>
        <p>ART not only prevents the perinatal transmission of HIV but also inhibits the sexual (secondary) transmission of the virus. The level of viral RNA in the blood and genital tract secretions of the mother is diminished by strict adherence to the ART regimen.<xref ref-type="bibr" rid="article-22931.r23">[23]</xref></p>
        <p>ART should be started as soon as a diagnosis of HIV is made in a pregnant patient or as soon as pregnancy is diagnosed in an HIV positive woman who is still untreated. This should be done regardless of the patient&#x02019;s CD4 count or HIV RNA levels. A combined antepartum, intrapartum, and postpartum (neonatal prophylaxis) approach should be adopted when administering ART to minimize the perinatal spread of HIV.<xref ref-type="bibr" rid="article-22931.r24">[24]</xref><xref ref-type="bibr" rid="article-22931.r25">[25]</xref><xref ref-type="bibr" rid="article-22931.r24">[24]</xref></p>
        <p>Before initiating ART, the patient must be informed about its possible side effects on the mother or fetus and interactions of ART drugs with other medications.<xref ref-type="bibr" rid="article-22931.r26">[26]</xref>&#x000a0;The importance of strict adherence to ART should also be stressed.<xref ref-type="bibr" rid="article-22931.r27">[27]</xref></p>
        <p>While choosing an ART regimen for pregnant women, a combination regimen is usually preferred over a single agent.<xref ref-type="bibr" rid="article-22931.r28">[28]</xref> At least one NRTI agent with significant trans-placental transfer should be added to the regimen to maximize the fetus&#x02019;s pre-exposure prophylaxis.<xref ref-type="bibr" rid="article-22931.r29">[29]</xref> The principles dictating the selection of ART regimen in pregnant women are the same as in non-pregnant HIV patients except certain regimens, which are avoided because of limited data about their dosing in pregnant women.</p>
        <p>For treatment-na&#x000ef;ve patients, two NRTIs with a third integrase inhibitor or protease inhibitor is the preferred regimen, keeping in view the results of the patient&#x02019;s drug resistance testing. Patient&#x02019;s tolerability, adherence, and comorbid conditions are also important factors affecting regimen selection. Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) or abacavir-lamivudine are generally used NRTI combinations. Tenofovir is avoided in patients with significant renal failure. Zidovudine-lamivudine, despite extensive use and demonstrated safety in pregnancy, is still only an alternative drug in the US. This is because it requires twice-daily dosing and causes headaches and anemia in the mother, along with congenital heart defects in the fetus.<xref ref-type="bibr" rid="article-22931.r30">[30]</xref> Popular third drug choices include the once-daily dose of the highly virologic integrase inhibitor dolutegravir (DTG) (associated with a small increased risk of neural tube defects (NTDs) with use at the time of conception) or twice-daily dosing of another highly virologic integrase inhibitor raltegravir (more prone to drug resistance).<xref ref-type="bibr" rid="article-22931.r31">[31]</xref> Another popular choice of a third agent is a protease inhibitor e.g., once-daily dosing of atazanavir-ritonavir (can cause indirect hyperbilirubinemia in mother) or twice-daily dosing of darunavir-ritonavir. However, there is a small risk of preterm birth with protease inhibitors, and they often require boosting due to the pharmacokinetic changes in pregnancy.</p>
        <p>Didanosine, stavudine, and full-dose ritonavir regimens must be discontinued during pregnancy even if the patient has successfully attained sustained viral suppression.<xref ref-type="bibr" rid="article-22931.r32">[32]</xref><xref ref-type="bibr" rid="article-22931.r33">[33]</xref></p>
        <p>For women who become pregnant while on ART with sustained viral suppression, continuing the same regimen during pregnancy is strongly encouraged. This is true even when the agents in their present regimen are not preferred during pregnancy. Patient&#x02019;s tolerability and adherence and dose adjustments (especially for protease inhibitors) to account for pharmacokinetic changes in pregnancy are still of utmost importance. Women on cobicistat-containing regimens at the time of pregnancy are encouraged to switch to an alternative drug because cobicistat&#x02019;s levels decrease during pregnancy, and there is a risk of loss of the previously sustained suppression of the virus.<xref ref-type="bibr" rid="article-22931.r34">[34]</xref> Women on dolutegravir should be counseled about the small risk of NTDs with DTG.<xref ref-type="bibr" rid="article-22931.r35">[35]</xref> In the US, The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission guidelines dictate the continuation of DTG in such cases.</p>
        <p>For women who become pregnant while on ART but without sustained suppression of the virus should be evaluated about drug adherence, and resistance testing should be done. Agents not usually recommended for use during pregnancy may be prescribed in this case. Once-daily dosing is preferred, and if there is still no viral suppression, repeat drug resistance testing should be done.<xref ref-type="bibr" rid="article-22931.r36">[36]</xref></p>
        <p>Women who were previously on ART but not currently taking it should be evaluated thoroughly about past drug regimens, virologic efficacy, past drug tolerability, and past resistance testing. Again, agents not usually preferred in pregnancy may be used in such cases. Patient adherence should be stressed, and viral response closely monitored.</p>
        <p>For women with high viral load (treatment na&#x000ef;ve or experienced) presenting late in pregnancy, the use of integrase inhibitors e.g., dolutegravir, has been found to result in a rapid decrease in HIV RNA load.<xref ref-type="bibr" rid="article-22931.r37">[37]</xref></p>
        <p>If an ART regimen has to be stopped during pregnancy e.g., due to drug toxicity, hyperemesis gravidarum, acute illness or lack of availability of drugs, all component drugs of the regimen must be discontinued together<xref ref-type="bibr" rid="article-22931.r38">[38]</xref>, and the priority should be to restart an ART regimen as soon as possible again.<xref ref-type="bibr" rid="article-22931.r39">[39]</xref><xref ref-type="bibr" rid="article-22931.r38">[38]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Intrapartum Management</bold>
</p>
          </list-item>
        </list>
        <p>Women with HIV RNA viral load &#x0003e;1000 copies/mL or unknown levels near delivery are delivered via scheduled cesarean section at 38 weeks.<xref ref-type="bibr" rid="article-22931.r40">[40]</xref>&#x000a0; Cesarean section is not indicated when HIV RNA viral load &#x0003c;1000 copies/mL, and the patient is on ART. HIV positive women are found to have a higher complication rate from cesarean section than HIV negative women.<xref ref-type="bibr" rid="article-22931.r41">[41]</xref> For women whose HIV RNA is &#x0003c;1000 copies/mL, the timing of vaginal delivery should follow the standard OB/GYN indications. If a scheduled cesarean delivery is performed for routine indications (other than HIV prevention) and HIV RNA is &#x0003c;1000 copies/mL, it should be performed at 39 weeks.<xref ref-type="bibr" rid="article-22931.r42">[42]</xref></p>
        <p>If a woman with HIV RNA &#x0003e;1000 copies/mL presents before 37 weeks with ruptured membranes or spontaneous labor, her individualized management plan should be decided after consulting with a perinatal HIV expert if a woman presenting with ruptured membranes has HIV RNA &#x0003c;1000 copies/mL, there is no increased risk of perinatal HIV transmission, and there is no indication for cesarean delivery.</p>
        <p>Artificial rupture of membrane for obstetrical indications can only be done if the patient is on ART with sustained viral suppression, though it should be used as a last alternative due to the risk of transmission of the virus due to injury to the fetus during the procedure. It must be avoided in women with detectable viral loads. Fetal scalp electrodes, forceps, or vacuum-assisted delivery should be avoided in all HIV positive women.</p>
        <p>In the case of uterine atony and postpartum hemorrhage, methergine should be avoided if the patient&#x02019;s ART regimen has a cytochrome CYP3A4 enzyme inhibitor e.g., cobicistat.<xref ref-type="bibr" rid="article-22931.r43">[43]</xref> An added dose of methergine is needed in patients taking CYP3A4 enzyme inducers, e.g., efavirenz.</p>
        <p>Routine ART regimen should be continued during the intrapartum management phase. If HIV RNA &#x0003e; 1000 copies/mL at the time of delivery, then IV zidovudine (ZDV) infusion should be started 3 hours prior to the scheduled cesarean section in addition to oral administration of routine ART regimen.<xref ref-type="bibr" rid="article-22931.r44">[44]</xref> If the routine ART regimen consists of ZDV, it can be stopped during this period of IV ZDV infusion. ZDV infusion must be given whenever HIV RNA&#x0003e; 1000 copies/mL at the time of delivery, even if ZDV was not a part of the routine ART regimen due to ZDV resistance. ZDV rapidly crosses the placenta and builds ART drug levels in the fetus&#x02019;s system before it is exposed to the mother&#x02019;s genital secretions and blood during delivery, which contains HIV.<xref ref-type="bibr" rid="article-22931.r45">[45]</xref></p>
        <p>If a woman presents in labor with unknown HIV status, offer her an opt-out screening option for HIV. The initial test is a combination immunoassay for HIV-1 and HIV-2 and an HIV RNA assay. If this initial test is positive, immediately start IV ZDV infusion. Women with positive initial tests are tested with antibody immunoassay, which differentiates HIV-1 and HIV-2 antibodies.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Postpartum Management </bold>
</p>
          </list-item>
        </list>
        <p>Comprehensive care plans involving OB/GYN, primary care, HIV specialists, pediatric care, mental health, and supportive care must be provided to HIV positive women in the postpartum period. ART for the mother and the newborn must be provided before hospital discharge, and the first follow-up visit to the HIV-care provider must happen within 2-4 weeks of discharge. These measures are of particular importance to women who have HIV diagnosed during delivery/labor and maximize the chances of successful viral suppression.<xref ref-type="bibr" rid="article-22931.r46">[46]</xref></p>
        <p>Postpartum depression is particularly important in HIV positive women, and all HIV positive women in postpartum must be screened for it.<xref ref-type="bibr" rid="article-22931.r47">[47]</xref> Postpartum adherence to ART is often challenging, and the continuation of postpartum ART must be stressed. In the postpartum phase, the choice of ART should be carefully tailored according to factors like the desire for future pregnancies, choice of contraceptives, and any potential drug interactions. Patients must be counseled about contraceptive use and PrEP for their partners (in serodiscordant couples) and informed about the earlier return of ovulation in the absence of breastfeeding.<xref ref-type="bibr" rid="article-22931.r48">[48]</xref> HIV positive women can safely use all methods of contraception.<xref ref-type="bibr" rid="article-22931.r49">[49]</xref><xref ref-type="bibr" rid="article-22931.r50">[50]</xref></p>
        <p>In the US official guidelines by the Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Infection state that breastfeeding must be avoided by HIV positive women because viral transmission through breast milk is possible despite ART suppression and also because of the risk of ART drug toxicity to the infant via breast milk. Women must be counseled about the various pharmacological and non-pharmacological options available to deal with painful breast engorgement when not breastfeeding.<xref ref-type="bibr" rid="article-22931.r51">[51]</xref><xref ref-type="bibr" rid="article-22931.r52">[52]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Newborn Management</bold>
</p>
          </list-item>
        </list>
        <p>Infants born to HIV positive mothers should be given ART post-exposure prophylaxis within 6&#x000a0;to 12 hours of delivery. Infants born to mothers with viral suppression should receive ZDV for four weeks unless the mother had genital ulcers or excessive bleeding or other STIs at the time of delivery, in which case the infant should receive the same care as that given to an infant born to a mother without viral suppression. Infants born to mothers with no viral suppression (HIV RNA&#x0003e;50copies/mL) should receive a two-drug (ZDV and nevirapine) or three-drug (ZDV, lamivudine, and either nevirapine or raltegravir) for six weeks.<xref ref-type="bibr" rid="article-22931.r45">[45]</xref> if the HIV status of the mother is unknown, give a rapid HIV antigen-antibody test to the mother. At the same time, the infant should be given two or three-drug prophylaxis (same as in high-risk infants). This prophylaxis can be stopped if the testing reveals that HIV is not present in the mother.</p>
        <p>A CBC with differential is performed before starting ART in infants. If abnormalities are detected on it, then ART may need to be stopped, a decision that should be made after consultation with pediatric HIV experts. As a general rule, hemoglobin and neutrophil counts should be measured every four weeks if an infant is receiving ZDV and lamivudine regimen.</p>
        <p>TMP-SMX prophylaxis against PCP is started after 4 or 6 weeks ART prophylaxis has finished in an infant born to a mother who is HIV positive unless definite test results are available to rule out HIV infection in the newborn. In infants &#x0003c;18 months, viral assays (HIV RNA or HIV DNA nucleic acid tests or NATs) are used to diagnose HIV. No antigen-antibody assays should be used. All infants born to HIV positive mothers are tested with NATs at 14&#x000a0;to 21 days, 1&#x000a0;to 2 months, and 4&#x000a0;to 6 months. If an infant is at high risk of HIV transmission (e.g., no viral suppression in the mother), additional NATs should be performed at birth and at 2&#x000a0;to 3 months.</p>
        <p>In utero or neonatal exposure to HIV or ART drugs must be documented in a child&#x02019;s long-term medical records even if the child is HIV negative. This is important because many such children have mitochondrial abnormalities leading to the development of disorders of the heart and nervous system in later life.<xref ref-type="bibr" rid="article-22931.r53">[53]</xref></p>
      </sec>
      <sec id="article-22931.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for acute HIV infection in pregnancy can include infectious mononucleosis (IM), syphilis, rubella, toxoplasmosis, viral hepatitis, disseminated gonococcal infection, or an autoimmune disease of new-onset.</p>
      </sec>
      <sec id="article-22931.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In the absence of any treatment, the risk of vertical transmission of HIV during pregnancy, delivery, or breastfeeding is as high as 25&#x000a0;to 30%. However, with rigorous testing, preconception counseling, good ART adherence, scheduled cesarean delivery, and infant prophylaxis, the rate of vertical transmission is as low as &#x0003c;1&#x000a0;to 2% in the US.<xref ref-type="bibr" rid="article-22931.r54">[54]</xref></p>
      </sec>
      <sec id="article-22931.s10" sec-type="Complications">
        <title>Complications</title>
        <p>In untreated HIV positive women, the risk of developing opportunistic infections increases with the fall in CD4 cell counts. Opportunistic infections like CMV and toxoplasmosis can cross the placenta and infect the fetus leading to congenital abnormalities. Also, untreated HIV infection has high chances of being passed on to the newborn in utero, during delivery, or by breastfeeding.</p>
        <p>ART regimens themselves are also associated with many complications. Dolutegravir is associated with NTDs, while protease inhibitors have been found to cause preterm birth.<xref ref-type="bibr" rid="article-22931.r33">[33]</xref> ZDV can cause hematological abnormalities in the infant.<xref ref-type="bibr" rid="article-22931.r55">[55]</xref> Similarly in utero exposure to HIV or ART drugs can also cause mitochondrial dysfunction later on in the child&#x02019;s life.<xref ref-type="bibr" rid="article-22931.r53">[53]</xref><xref ref-type="bibr" rid="article-22931.r35">[35]</xref></p>
      </sec>
      <sec id="article-22931.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients&#x02019; reasons for opting out of HIV testing during their initial prenatal visit should be explored. Testing should again be offered in the third trimester to women who opt out in the first trimester or those included in high-risk groups according to the CDC (e.g., IV drug users and their sexual partners, women who are sex workers, sexual partners of HIV-infected persons, and women with a new or more than one sexual partner during this pregnancy)</p>
        <p>HIV positive women must be counseled about the need to achieve sustained viral suppression before conception and the importance of ART adherence in minimizing both vertical and secondary sexual transmission of the virus to their partners. They should also be counseled against unsafe sexual practices, alcohol and tobacco use, and illicit drug abuse.<xref ref-type="bibr" rid="article-22931.r49">[49]</xref></p>
        <p>Patients must be educated about the various available methods of contraception,&#x000a0;the availability of PrEP for their HIV-negative partners, the need to avoid breastfeeding, and how to alleviate painful breast engorgement in the absence of lactation.<xref ref-type="bibr" rid="article-22931.r51">[51]</xref><xref ref-type="bibr" rid="article-22931.r52">[52]</xref></p>
      </sec>
      <sec id="article-22931.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing HIV in pregnant women requires an interprofessional team of healthcare professionals that includes a nurse, laboratory technologists, pharmacists, social workers, and a number of physicians in different specialties. Without proper management, the rate of perinatal transmission of HIV from mother-to-child is high.<xref ref-type="bibr" rid="article-22931.r1">[1]</xref>[Level V]</p>
        <p>The moment an HIV positive woman expresses her desire to have a child, the clinic physician and nurse are required to assess her readiness as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The nurse orders her CD4 cell counts and viral load measurements and coordinates with the laboratory technologists.</p>
          </list-item>
          <list-item>
            <p>The physician assesses her adherence to the ART regimen and consults with the pharmacist about the need to switch regimens in case one of the drugs is contraindicated in pregnancy.<xref ref-type="bibr" rid="article-22931.r56">[56]</xref>&#x000a0;[Level V]</p>
          </list-item>
          <list-item>
            <p>The primary care physician or HIV specialist consults OB/GYN specialists, and together they coordinate to care for the special needs of an HIV positive pregnant patient.</p>
          </list-item>
          <list-item>
            <p>Mental health physician is consulted to evaluate the patient for any domestic violence, depression or anxiety as these could affect her ART adherence and jeopardize the health and ensure the wellbeing of both the mother and the child.</p>
          </list-item>
          <list-item>
            <p>OB/GYN specialist plans the mode and timing of delivery [Level V] and coordinates with the patient&#x02019;s HIV specialist, mental health physician and HIV pediatric specialist to improve the patient&#x02019;s ART adherence postpartum, screen for postpartum depression and provide ART prophylaxis and testing to the newborn.</p>
          </list-item>
        </list>
        <p>The management of HIV positive pregnant patient does not end with the delivery of the baby. ART regimens for both the mother and the child have to be decided before hospital discharge. Future contraception options have to be discussed. Counseling about breastfeeding needs to be done. The patient&#x02019;s family support and home environment need to be assessed by a social worker. Only by working as an interprofessional team can we minimize the perinatal transmission of HIV.<xref ref-type="bibr" rid="article-22931.r54">[54]</xref><xref ref-type="bibr" rid="article-22931.r57">[57]</xref>&#x000a0;[Level V]</p>
      </sec>
      <sec id="article-22931.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22931&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22931">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-in-pregnancy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22931">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22931/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22931">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22931.s14">
        <title>References</title>
        <ref id="article-22931.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diwan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development.</article-title>
            <source>Springerplus</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">23483108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesheim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>FitzHarris</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lampe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Reconsidering the Number of Women With HIV Infection Who Give Birth Annually in the United States.</article-title>
            <source>Public Health Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>133</volume>
            <issue>6</issue>
            <fpage>637</fpage>
            <page-range>637-643</page-range>
            <pub-id pub-id-type="pmid">30265616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sconza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S Peckham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tookey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>UK Mother-to-Child HIV Transmission Rates Continue to Decline: 2012-2014.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>527</fpage>
            <page-range>527-528</page-range>
            <pub-id pub-id-type="pmid">28174911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giroir</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>The Time Is Now to End the HIV Epidemic.</article-title>
            <source>Am J Public Health</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-24</page-range>
            <pub-id pub-id-type="pmid">31725312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mongelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gardosi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Estimating the date of confinement: ultrasonographic biometry versus certain menstrual dates.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>174</volume>
            <issue>1 Pt 1</issue>
            <fpage>278</fpage>
            <page-range>278-81</page-range>
            <pub-id pub-id-type="pmid">8572021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuomala</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kalish</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Zorilla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shearer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Landay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermund</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Landesman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study.</article-title>
            <source>Obstet Gynecol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>967</fpage>
            <page-range>967-74</page-range>
            <pub-id pub-id-type="pmid">9170476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sheffield</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Grimes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McElwee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Laibl</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McIntire</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Wendel</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Effect of protease inhibitor therapy on glucose intolerance in pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2006</year>
            <month>May</month>
            <volume>107</volume>
            <issue>5</issue>
            <fpage>1115</fpage>
            <page-range>1115-9</page-range>
            <pub-id pub-id-type="pmid">16648418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polis</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Apr</month>
            <day>15</day>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>1123</fpage>
            <page-range>1123-31</page-range>
            <pub-id pub-id-type="pmid">17366462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>1998</year>
            <month>Oct</month>
            <day>30</day>
            <volume>47</volume>
            <issue>RR-20</issue>
            <fpage>1</fpage>
            <page-range>1-58</page-range>
            <pub-id pub-id-type="pmid">9809743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schlegel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirschel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cavassini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernasconi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rickenbach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>H</given-names>
              </name>
              <collab>Swiss HIV Cohort Study</collab>
            </person-group>
            <article-title>Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Jan</month>
            <day>01</day>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-102</page-range>
            <pub-id pub-id-type="pmid">17143823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mwapasa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rogerson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kwiek</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Milner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molyneux</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kamwendo</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Tadesse</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chaluluka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meshnick</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi.</article-title>
            <source>AIDS</source>
            <year>2006</year>
            <month>Sep</month>
            <day>11</day>
            <volume>20</volume>
            <issue>14</issue>
            <fpage>1869</fpage>
            <page-range>1869-77</page-range>
            <pub-id pub-id-type="pmid">16954728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinn</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Piot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Feinsod</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Taelman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kapita</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fauci</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection.</article-title>
            <source>JAMA</source>
            <year>1987</year>
            <month>May</month>
            <day>15</day>
            <volume>257</volume>
            <issue>19</issue>
            <fpage>2617</fpage>
            <page-range>2617-21</page-range>
            <pub-id pub-id-type="pmid">3494857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czeizel</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Rockenbauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study.</article-title>
            <source>Reprod Toxicol</source>
            <year>2001</year>
            <season>Nov-Dec</season>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>637</fpage>
            <page-range>637-46</page-range>
            <pub-id pub-id-type="pmid">11738517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shubber</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Frigati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mofenson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2014</year>
            <month>Aug</month>
            <day>15</day>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-21</page-range>
            <pub-id pub-id-type="pmid">24853309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodger</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cambiano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bruun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vernazza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Lunzen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corbelli</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geretti</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Beloukas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asboe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Viciana</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Clotet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pradier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gerstoft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Westling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wandeler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rieger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoeckle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000fc;mmerle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ammassari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krznaric</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ristola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zangerle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Handberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>J</given-names>
              </name>
              <collab>PARTNER Study Group</collab>
            </person-group>
            <article-title>Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>316</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-81</page-range>
            <pub-id pub-id-type="pmid">27404185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Romero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baza</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>R&#x000ed;o</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jer&#x000f3;nimo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hernando</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Castilla</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>95</volume>
            <issue>30</issue>
            <fpage>e4398</fpage>
            <pub-id pub-id-type="pmid">27472733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeten</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Heffron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kidoguchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mugo</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Katabira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bukusi</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Asiimwe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haberer</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ngure</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bulya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Odoyo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tindimwebwa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hendrix</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marzinke</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haugen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mujugira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celum</surname>
                <given-names>C</given-names>
              </name>
              <collab>Partners Demonstration Project Team</collab>
            </person-group>
            <article-title>Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.</article-title>
            <source>PLoS Med</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e1002099</fpage>
            <pub-id pub-id-type="pmid">27552090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Natural Conception May Be an Acceptable Option in HIV-Serodiscordant Couples in Resource Limited Settings.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>e0142085</fpage>
            <pub-id pub-id-type="pmid">26540103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandelbrot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tubiana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Le Chenadec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dollfus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pannier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Matheron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khuong</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garrait</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reliquet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berrebi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allisy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elleau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arvieux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rouzioux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Warszawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <collab>ANRS-EPF Study Group</collab>
            </person-group>
            <article-title>No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>61</volume>
            <issue>11</issue>
            <fpage>1715</fpage>
            <page-range>1715-25</page-range>
            <pub-id pub-id-type="pmid">26197844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hitti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Agnew</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Luque</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Coombs</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-9</page-range>
            <pub-id pub-id-type="pmid">20929397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dulioust</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guibert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kunstmann</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Heard</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Juillard</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Leruez-Ville</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mandelbrot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rouzioux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sicard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zorn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jouannet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Almeida</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Semen alterations in HIV-1 infected men.</article-title>
            <source>Hum Reprod</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>2112</fpage>
            <page-range>2112-8</page-range>
            <pub-id pub-id-type="pmid">12151446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savasi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Oneta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laoreti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parisi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Parrilla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Duca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cetin</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effects of Antiretroviral Therapy on Sperm DNA Integrity of HIV-1-Infected Men.</article-title>
            <source>Am J Mens Health</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1835</fpage>
            <page-range>1835-1842</page-range>
            <pub-id pub-id-type="pmid">30132391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pilotto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Velasque</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Veloso</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.</article-title>
            <source>Antivir Ther</source>
            <year>2011</year>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">21555817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taha</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kumwenda</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Broadhead</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Fiscus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lema</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liomba</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nkhoma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miotti</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Oct</month>
            <day>11</day>
            <volume>362</volume>
            <issue>9391</issue>
            <fpage>1171</fpage>
            <page-range>1171-7</page-range>
            <pub-id pub-id-type="pmid">14568737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Brogly</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Muenz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stek</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>JS</given-names>
              </name>
              <collab>International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) P1025 Study Team</collab>
            </person-group>
            <article-title>Missed Opportunities for Prevention of Mother-to-Child Transmission of Human Immunodeficiency Virus.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>621</fpage>
            <page-range>621-628</page-range>
            <pub-id pub-id-type="pmid">28277349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grignolo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agnello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gerbaldo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gotta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alicino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Del Puente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Taramasso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruzzone</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gustavino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trasino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DE Maria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Icardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Viscoli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DI Biagio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study.</article-title>
            <source>Epidemiol Infect</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>145</volume>
            <issue>8</issue>
            <fpage>1658</fpage>
            <page-range>1658-1669</page-range>
            <pub-id pub-id-type="pmid">28325171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Leister</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kacanek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bardeguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Tuomala</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study.</article-title>
            <source>Ann Intern Med</source>
            <year>2015</year>
            <month>Jan</month>
            <day>20</day>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-9</page-range>
            <pub-id pub-id-type="pmid">25599347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fowler</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiscus</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chipato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gnanashanmugam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Siberry</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Coletti</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Taha</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Klingman</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Martinson</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Owor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Violari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Theron</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Bhosale</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bobat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Strehlau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mlay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loftis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fenton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Basar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Mofenson</surname>
                <given-names>LM</given-names>
              </name>
              <collab>IMPAACT 1077BF/1077FF PROMISE Study Team</collab>
            </person-group>
            <article-title>Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>03</day>
            <volume>375</volume>
            <issue>18</issue>
            <fpage>1726</fpage>
            <page-range>1726-1737</page-range>
            <pub-id pub-id-type="pmid">27806243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>989</fpage>
            <page-range>989-1004</page-range>
            <pub-id pub-id-type="pmid">25223699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sibiude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le Chenadec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tubiana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Faye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dollfus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mandelbrot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lelong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khoshnood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Warszawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <collab>French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial</collab>
            </person-group>
            <article-title>In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.</article-title>
            <source>Clin Infect Dis</source>
            <year>2015</year>
            <month>Jul</month>
            <day>15</day>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>270</fpage>
            <page-range>270-80</page-range>
            <pub-id pub-id-type="pmid">25838291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zash</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Makhema</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>06</day>
            <volume>379</volume>
            <issue>10</issue>
            <fpage>979</fpage>
            <page-range>979-981</page-range>
            <pub-id pub-id-type="pmid">30037297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <article-title>d4T plus ddI: warning for pregnant women.</article-title>
            <source>AIDS Treat News</source>
            <year>2001</year>
            <month>Jan</month>
            <day>12</day>
            <issue>358</issue>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">12173560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kitch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ogwu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lockman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leidner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Widenfelt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moffat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moyo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Makhema</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Essex</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy.</article-title>
            <source>J Infect Dis</source>
            <year>2011</year>
            <month>Aug</month>
            <day>15</day>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>506</fpage>
            <page-range>506-14</page-range>
            <pub-id pub-id-type="pmid">21791651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Struble</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sherwat</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.</article-title>
            <source>AIDS</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-1093</page-range>
            <pub-id pub-id-type="pmid">30946163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zash</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Diseko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayondi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mmalane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Essex</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gaolethe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petlo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lockman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Makhema</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.</article-title>
            <source>Lancet Glob Health</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>7</issue>
            <fpage>e804</fpage>
            <page-range>e804-e810</page-range>
            <pub-id pub-id-type="pmid">29880310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tedaldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Armon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nesheim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lampe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buchacz</surname>
                <given-names>K</given-names>
              </name>
              <collab>HOPS Investigators</collab>
            </person-group>
            <article-title>HIV RNA Suppression during and after Pregnancy among Women in the HIV Outpatient Study, 1996 to 2015.</article-title>
            <source>J Int Assoc Provid AIDS Care</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>17</volume>
            <fpage>2325957417752259</fpage>
            <pub-id pub-id-type="pmid">29357772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waitt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Orrell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walimbwa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kintu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaboggoza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sihlangu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coombs</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Malaba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Byamugisha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Else</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heiburg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hodel</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Byakika-Kibwika</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Myer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lamorde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A&#x000a0;randomised trial (DolPHIN-1 study).</article-title>
            <source>PLoS Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>e1002895</fpage>
            <pub-id pub-id-type="pmid">31539371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Puliti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chiappini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gabiano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferraris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mignone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giaquinto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Genovese</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Anzidei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Badolato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buffolano</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maccabruni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cellini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manzionna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tovo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de Martino</surname>
                <given-names>M</given-names>
              </name>
              <collab>Italian Register for HIV Infection in Children</collab>
            </person-group>
            <article-title>Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>May</month>
            <day>01</day>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>1310</fpage>
            <page-range>1310-7</page-range>
            <pub-id pub-id-type="pmid">19309307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geretti</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lipscomb</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stuyver</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tachedjian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Touloumi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>A</given-names>
              </name>
              <collab>INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group</collab>
            </person-group>
            <article-title>Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>e69266</fpage>
            <pub-id pub-id-type="pmid">23874928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 751: Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e131</fpage>
            <page-range>e131-e137</page-range>
            <pub-id pub-id-type="pmid">30134427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kourtis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ellington</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pazol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Complications of cesarean deliveries among HIV-infected women in the United States.</article-title>
            <source>AIDS</source>
            <year>2014</year>
            <month>Nov</month>
            <day>13</day>
            <volume>28</volume>
            <issue>17</issue>
            <fpage>2609</fpage>
            <page-range>2609-18</page-range>
            <pub-id pub-id-type="pmid">25574961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tita</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Landon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Spong</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leveno</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Varner</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Moawad</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Caritis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Meis</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wapner</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sorokin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miodovnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peaceman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sibai</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Thorp</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ramin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>BM</given-names>
              </name>
              <collab>Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network</collab>
            </person-group>
            <article-title>Timing of elective repeat cesarean delivery at term and neonatal outcomes.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Jan</month>
            <day>08</day>
            <volume>360</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-20</page-range>
            <pub-id pub-id-type="pmid">19129525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burgos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Torrella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oca&#x000f1;a</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Falc&#x000f3;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.</article-title>
            <source>Antivir Ther</source>
            <year>2017</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-90</page-range>
            <pub-id pub-id-type="pmid">27546463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bardeguez</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fridland</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants.</article-title>
            <source>J Infect Dis</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>180</volume>
            <issue>6</issue>
            <fpage>1844</fpage>
            <page-range>1844-50</page-range>
            <pub-id pub-id-type="pmid">10558940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen-Saines</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Veloso</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Joao</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Pilotto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Theron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreitchmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mussi-Pinhata</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ceriotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bethel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Dickover</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camarca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirochnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siberry</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bastos</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moye</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mofenson</surname>
                <given-names>LM</given-names>
              </name>
              <collab>NICHD HPTN 040/PACTG 1043 Protocol Team</collab>
            </person-group>
            <article-title>Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jun</month>
            <day>21</day>
            <volume>366</volume>
            <issue>25</issue>
            <fpage>2368</fpage>
            <page-range>2368-79</page-range>
            <pub-id pub-id-type="pmid">22716975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Momplaisir</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Corson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Assessing the Impact of Perinatal HIV Case Management on Outcomes Along the HIV Care Continuum for Pregnant and Postpartum Women Living With HIV, Philadelphia 2005-2013.</article-title>
            <source>AIDS Behav</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>2670</fpage>
            <page-range>2670-2681</page-range>
            <pub-id pub-id-type="pmid">28176167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossom</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Henninger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Groom</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Burda</surname>
                <given-names>BU</given-names>
              </name>
            </person-group>
            <article-title>Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jan</month>
            <day>26</day>
            <volume>315</volume>
            <issue>4</issue>
            <fpage>388</fpage>
            <page-range>388-406</page-range>
            <pub-id pub-id-type="pmid">26813212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glasier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Return of ovulation and menses in postpartum nonlactating women: a systematic review.</article-title>
            <source>Obstet Gynecol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>657</fpage>
            <page-range>657-662</page-range>
            <pub-id pub-id-type="pmid">21343770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polis</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>797</fpage>
            <page-range>797-808</page-range>
            <pub-id pub-id-type="pmid">23871397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sawatphanit</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takeo</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Depressive symptoms among HIV-positive postpartum women in Thailand.</article-title>
            <source>Arch Psychiatr Nurs</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-42</page-range>
            <pub-id pub-id-type="pmid">21251600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 736: Optimizing Postpartum Care.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>e140</fpage>
            <page-range>e140-e150</page-range>
            <pub-id pub-id-type="pmid">29683911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tulloch</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dodin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tremblay-Racine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Elwood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Money</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boucoiran</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Cabergoline: a review of its use in the inhibition of lactation for women living with HIV.</article-title>
            <source>J Int AIDS Soc</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>e25322</fpage>
            <pub-id pub-id-type="pmid">31183987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>734</fpage>
            <page-range>734-40</page-range>
            <pub-id pub-id-type="pmid">24378947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesheim</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>FitzHarris</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Mahle Gray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lampe</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Perinatal HIV Transmission in the United States in the Era of Its Elimination.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>611</fpage>
            <page-range>611-616</page-range>
            <pub-id pub-id-type="pmid">30724833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taha</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kumwenda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kafulafula</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kumwenda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chitale</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nkhoma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Katundu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mukiibi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Broadhead</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth.</article-title>
            <source>Ann Trop Paediatr</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-9</page-range>
            <pub-id pub-id-type="pmid">15720887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kalish</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Minkoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Burchett</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kornegay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moye</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zorrilla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Aug</month>
            <day>05</day>
            <volume>341</volume>
            <issue>6</issue>
            <fpage>394</fpage>
            <page-range>394-402</page-range>
            <pub-id pub-id-type="pmid">10432324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22931.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briand</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jasseron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sibiude</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Azria</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pollet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hammou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Warszawski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mandelbrot</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>209</volume>
            <issue>4</issue>
            <fpage>335.e1</fpage>
            <page-range>335.e1-335.e12</page-range>
            <pub-id pub-id-type="pmid">23791563</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
